Prostate Cancer

Latest News

Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC
Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC

June 2nd 2025

Data also showed a positive trend in overall survival.

A. Oliver Sartor, MD
Long-term data support radium-223 safety in mCRPC

June 2nd 2025

FDA updates in urology: May 2025
FDA updates in urology: May 2025

June 2nd 2025

Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
PEACE-3 data for radium-223/enzalutamide published in Annals of Oncology

May 30th 2025

Phase 2 trial launches of combination immunotherapy for mCRPC
Phase 2 trial launches of combination immunotherapy for mCRPC

May 30th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.